newsHowie Mandel challenges people to learn the fibs and facts about atrial fibrillation and its associated increased stroke risk28 October 2013 | By Bristol-Myers Squibb“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
newsPromising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented28 October 2013 | By Bristol-Myers Squibb CompanyClazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
newsPromising phase IIb data on Clazakizumab in patients with moderate-to-severe Rheumatoid Arthritis to be presented28 October 2013 | By Bristol-Myers Squibb CompanyClazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
newsBristol-Myers Squibb to present range of new hepatitis C data at the 2013 American Association for the study of liver diseases (AASLD) annual meeting1 October 2013 | By Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...
newsNew Phase III data showed Dapagliflozin significantly reduced HbA1c compared to placebo25 September 2013 | By Bristol-Myers Squibb CompanyAt 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
newsBristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer12 September 2013 | By Bristol-Myers Squibb CompanyResults from the Phase 3 randomized, double-blind clinical trial (Study 043)...
newsSubanalysis of Phase III ARISTOTLE trial of Eliquis® (apixaban) demonstrated consistent results versus warfarin in patients with NVAF with or without valvular heart disease3 September 2013 | By PfizerData show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
newsONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial2 September 2013 | By AstraZenecaSAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
newsNew Eliquis® (apixaban) post-hoc subanalysis of the Phase III ARISTOTLE trial demonstrated that within 30 days of a procedure, stroke or systemic embolism and major bleeding were uncommon31 August 2013 | By PfizerResults presented at the ESC Congress 2013...
newsBristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship29 July 2013 | By Bristol-Myers Squibb CompanyBristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement...
newsUS FDA acknowledges receipt of resubmission of the New Drug Application for investigational compound dapagliflozin for the treatment of type 2 diabetes25 July 2013 | By AstraZenecaThe US FDA has acknowledged receipt of the NDA resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes...
newsAstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S25 July 2013 | By AstraZenecaNDA for dapagliflozin resubmitted to FDA...
newsBristol-Myers Squibb partners with the Centers for Disease Control Foundation23 July 2013 | By Bristol-Myers Squibb CompanyJoint effort supports early disease identification to connect at-risk patients to necessary care...
newsFDA accepts Eliquis® (apixaban) sNDA for review for prophylaxis of deep vein thrombosis following hip or knee replacement surgery11 July 2013 | By Bristol-Myers Squibb CompanyFDA accepted for review a sNDA for Eliquis®
newsFDA approves U.S. product labeling update for Sprycel®20 June 2013 | By Bristol-Myers Squibb CompanyData added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options...
